Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
发现 NF1 周围神经鞘瘤进展的治疗靶点
基本信息
- 批准号:10439480
- 负责人:
- 金额:$ 57.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressBenignC57BL/6 MouseCDKN2A geneCell LineCellsChemicalsClustered Regularly Interspaced Short Palindromic RepeatsDNA sequencingDetectionDevelopmentDrug ScreeningDrug TargetingEnvironmentEpigenetic ProcessErinaceidaeEvolutionGenesGeneticGenetic DiseasesGenetic ScreeningGenetically Engineered MouseGenotypeGoalsHeritabilityHumanImage AnalysisImmuneImmune systemImmunocompromised HostIn VitroLesionLethal GenesLifeMalignant - descriptorMalignant NeoplasmsMethodsModelingModificationMolecular TargetMorbidity - disease rateMusMutationNF1 geneNeoplasmsNerveNerve Sheath TumorsNeurofibromatosesNeurofibromatosis 1NeurofibrosarcomaOperative Surgical ProceduresPainPatientsPerinatalPeripheral Nerve Sheath NeoplasmPeripheral NervesPersonsPharmaceutical PreparationsPlexiform NeurofibromaPopulationPre-Clinical ModelPreclinical TestingPremalignant CellPreventionProcessPrognosisProtein Phosphatase 2A Regulatory Subunit PR53RoleSchwann CellsSoft tissue sarcomaSourceSyndromeSystemTestingTherapeutic UsesTissuesWild Type Mousebasecancer predispositioncell transformationchemotherapydermal neurofibromadrug candidateexomegene productgenetically modified cellshuman dataimmunoregulationin vitro Modelin vitro testingin vivoin vivo Modelindexinginduced pluripotent stem cellloss of function mutationmolecular targeted therapiesmortalitymouse modelmutantneurofibromanew therapeutic targetnovel therapeuticspreventrecruitsciatic nervesubcutaneoustranscriptometranscriptome sequencingtransplant modeltumortumor progressiontumor-immune system interactions
项目摘要
Project Summary/Abstract
Neurofibromatosis type 1 (NF1) syndrome is an autosomal dominant cancer-predisposing syndrome afflicting
~1 in every 3,500 persons worldwide with the majority of patients developing benign plexiform and/or dermal
neurofibromas. Plexiform neurofibromas constitute a lifelong source of disfigurement, morbidity and mortality,
and have the potential to transform to a malignant peripheral nerve sheath tumor (MPNST), an aggressive soft
tissue sarcoma. In fact, approximately 15% of NF1 patients develop poor prognosis MPNSTs, often in the
second or third decade of life. Treatment options for MPNSTs are limited to complicated surgical procedures
and classical chemotherapy and, so far, molecular targeted therapies have demonstrated limited efficacy. We
desperately need new treatment options for the MPNSTs and methods to prevent them from development. It
was recently found that plexiform neurofibromas progress to MPNST via an intermediate, “atypical”
neurofibroma (ANF) that in 70% of tumors shows heterozygous or homozygous loss of CDKN2A the gene
encoding p16INK4a and p14ARF (Beert et al., 2011; Pemov et al., 2018). Our proposal will address critical unmet
needs in this field, including better in vitro and in vivo models of ANF and identification of critical vulnerabilities
of these cells. To provide a model for preclinical testing and prevention of ANF to MPNST development, we
combined Desert hedgehog (Dhh)-Cre driven biallelic deletion of Nf1 with heterozygous loss of Cdkn2a,
creating a unique model of transplantable ANF developing within pre-existing neurofibroma (Chaney et al.,
submitted). We also combined Dhh-Cre driven biallelic deletion of Nf1 and Pten, generating rapidly developing
perinatal ANF-like lesions (Keng et al., 2012). ANF from Dhh-Cre;Nf1fl/fl;Cdkn2a+/- mice grafted
subcutaneously into immunocompromised hosts grew, after a delay, providing a more rapid, tractable,
transformation system. We plan a complete transcriptome and exome analysis in these models (Aim 1a), and
further investigate the model by identifying and validating cell populations and markers altered in mouse
and human PNF, ANF, and MPNST in unperturbed tissue sections using a new image analysis
method called CO-Detection by IndEXing (Aim 1b). Modulation of the immune environment is increasing
used therapeutically. We will therefore define the influence of the nerve microenvironment and immune system
on progression from ANF to MPNST (Aim 1c). To identify ANF vulnerabilities, we have completed drug and
CRISPR-based genetic synthetic lethality screens in isogenic immortalized human Schwann cells that are NF1
wildtype or were made homozygous for NF1 loss of function mutations using gene editing. Candidate drugs
that inhibit PP2A, and other novel targets from the drug screening effort, will be tested for their effects in ANF-
like cells in vitro (Aim 2a) and, when successful, in our unique GEMMs (Aim 2b). Similarly, our genetic
screening effort will be used to define additional vulnerabilities tested in vitro (Aim 2c) and in vivo (Aim 2d).
项目总结/摘要
1型神经纤维瘤病(NF 1)综合征是一种常染色体显性遗传的癌症易感综合征,
全球每3,500人中约有1人,大多数患者发生良性丛状和/或真皮
神经纤维瘤丛状神经纤维瘤构成了终身的毁容,发病率和死亡率的来源,
并有可能转化为恶性外周神经鞘瘤(MPNST),一种侵袭性的软组织肿瘤。
组织肉瘤事实上,大约15%的NF 1患者发展为预后不良的MPNST,通常在
人生的第二或第三个十年。MPNST的治疗选择仅限于复杂的外科手术
传统的化疗和分子靶向治疗已经显示出有限的疗效。我们
他们迫切需要新的治疗方案和方法来防止他们的发展。它
最近发现丛状神经纤维瘤通过中间的“非典型”
神经纤维瘤(ANF),在70%的肿瘤中显示CDKN 2A基因的杂合或纯合缺失,
编码p16 INK 4a和p14 ARF(Beert等人,2011; Pemov等人,2018年)。我们的建议将解决关键的未满足的
该领域的需求,包括更好的ANF体外和体内模型以及关键脆弱性的识别
这些细胞。为了提供临床前检测和预防ANF向MPNST发展的模型,我们
结合沙漠刺猬(Dhh)-Cre驱动的Nf 1双等位基因缺失和Cdkn 2a杂合缺失,
建立了在预先存在的神经纤维瘤内形成的可移植ANF的独特模型(Chaney等,
提交)。我们还结合了Dhh-Cre驱动的Nf 1和Pten的双等位基因缺失,
围产期ANF样病变(Keng等,2012年)。来自Dhh-Cre; Nf 1fl/fl; Cdkn 2a +/-小鼠移植的ANF
皮下移植到免疫功能低下的宿主中,在延迟后,提供了一种更快速,更易处理,
转换系统我们计划在这些模型中进行完整的转录组和外显子组分析(Aim 1a),
通过鉴定和验证小鼠中改变的细胞群和标记物来进一步研究该模型。
和人类PNF,ANF,和MPNST在未扰动的组织切片中使用新的图像分析
通过IndEXing(目标1b)进行CO检测。免疫环境的调节正在增加
用于治疗。因此,我们将定义神经微环境和免疫系统的影响
从ANF进展为MPNST(目标1c)。为了识别ANF的漏洞,我们已经完成了药物和
基于CRISPR的遗传合成致死性筛选在NF 1的同基因永生化人雪旺细胞中
野生型或使用基因编辑使NF 1功能缺失突变纯合。候选药物
抑制PP 2A和其他来自药物筛选工作的新靶点,将测试它们在ANF中的作用。
如体外细胞(Aim 2a),成功后,在我们独特的GEMM中(Aim 2b)。同样,我们的基因
筛选工作将用于定义体外(目标2c)和体内(目标2d)测试的其他漏洞。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID ANDREW LARGAESPADA其他文献
DAVID ANDREW LARGAESPADA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID ANDREW LARGAESPADA', 18)}}的其他基金
Integrated Immune Engineering for Poor Prognosis Cancers
综合免疫工程治疗预后不良的癌症
- 批准号:
10700921 - 财政年份:2021
- 资助金额:
$ 57.74万 - 项目类别:
Integrated Immune Engineering for Poor Prognosis Cancers
综合免疫工程治疗预后不良的癌症
- 批准号:
10270392 - 财政年份:2021
- 资助金额:
$ 57.74万 - 项目类别:
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
发现 NF1 周围神经鞘瘤进展的治疗靶点
- 批准号:
10653687 - 财政年份:2020
- 资助金额:
$ 57.74万 - 项目类别:
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
发现 NF1 周围神经鞘瘤进展的治疗靶点
- 批准号:
10247078 - 财政年份:2020
- 资助金额:
$ 57.74万 - 项目类别:
Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention
复发性肿瘤特异性交替加工转录本作为 NF1 相关恶性周围神经鞘肿瘤免疫预防的新抗原来源
- 批准号:
10488079 - 财政年份:2019
- 资助金额:
$ 57.74万 - 项目类别:
Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention
复发性肿瘤特异性交替加工转录本作为 NF1 相关恶性周围神经鞘肿瘤免疫预防的新抗原来源
- 批准号:
10465297 - 财政年份:2019
- 资助金额:
$ 57.74万 - 项目类别:
Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention
复发性肿瘤特异性交替加工转录本作为 NF1 相关恶性周围神经鞘肿瘤免疫预防的新抗原来源
- 批准号:
10023258 - 财政年份:2019
- 资助金额:
$ 57.74万 - 项目类别:
Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention
复发性肿瘤特异性交替加工转录本作为 NF1 相关恶性周围神经鞘肿瘤免疫预防的新抗原来源
- 批准号:
10662510 - 财政年份:2019
- 资助金额:
$ 57.74万 - 项目类别:
Center for Modeling Tumor Cell Migration Mechanics
肿瘤细胞迁移机制建模中心
- 批准号:
9901832 - 财政年份:2016
- 资助金额:
$ 57.74万 - 项目类别:
Center for Modeling Tumor Cell Migration Mechanics
肿瘤细胞迁移机制建模中心
- 批准号:
9753166 - 财政年份:2016
- 资助金额:
$ 57.74万 - 项目类别:
相似海外基金
Genome analysis-based prediction model development for response to stereotactic radiosurgery in benign brain tumors
基于基因组分析的预测模型开发,用于良性脑肿瘤立体定向放射外科治疗的反应
- 批准号:
23K08495 - 财政年份:2023
- 资助金额:
$ 57.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
- 批准号:
10719777 - 财政年份:2023
- 资助金额:
$ 57.74万 - 项目类别:
Environmentally Benign Precise Transformations of Alkenes by Chiral Chalcogenide Catalysts
手性硫属化物催化剂对环境无害的烯烃精确转化
- 批准号:
22KJ2498 - 财政年份:2023
- 资助金额:
$ 57.74万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Learners to LeAders in benign Urology, benign Nephrology, and non-Cancer Hematology
良性泌尿外科、良性肾脏病学和非癌症血液学领域的学习者和领导者
- 批准号:
10726042 - 财政年份:2023
- 资助金额:
$ 57.74万 - 项目类别:
The role of estrogen receptor alpha in prostatic fibrosis contributing to benign prostatic hyperplasia
雌激素受体α在导致良性前列腺增生的前列腺纤维化中的作用
- 批准号:
10607151 - 财政年份:2023
- 资助金额:
$ 57.74万 - 项目类别:
Development of a medical device to resolve benign esophageal stricture by heating and traction
开发通过加热和牵引解决良性食管狭窄的医疗设备
- 批准号:
23H03765 - 财政年份:2023
- 资助金额:
$ 57.74万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of benign/malignant differentiation method for thyroid follicular tumor using organoids
利用类器官开发甲状腺滤泡性肿瘤良恶性鉴别方法
- 批准号:
23K08075 - 财政年份:2023
- 资助金额:
$ 57.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis
p53在散发性肿瘤发生良性向恶性转变中的参与和作用机制
- 批准号:
10720034 - 财政年份:2023
- 资助金额:
$ 57.74万 - 项目类别:
I-Corps: Mitigating Multidrug Resistant Bacterial Infections with Biocompatible and Environmentally Benign Nanoantibiotics
I-Corps:利用生物相容性且对环境无害的纳米抗生素减轻多重耐药细菌感染
- 批准号:
2306943 - 财政年份:2023
- 资助金额:
$ 57.74万 - 项目类别:
Standard Grant
Identifying the role of the gut microbiome in the etiology of benign breast disease
确定肠道微生物组在良性乳腺疾病病因学中的作用
- 批准号:
10359959 - 财政年份:2022
- 资助金额:
$ 57.74万 - 项目类别:














{{item.name}}会员




